PT  - JOURNAL ARTICLE
AU  - Mumtaz, Rida
AU  - Okell, Lucy C.
AU  - Challenger, Joseph D.
TI  - How often do symptoms return after unsuccessful drug treatment for malaria? A systematic review and meta-analysis
AID  - 10.1101/2020.08.21.20179382
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.21.20179382
4099  - http://medrxiv.org/content/early/2020/08/25/2020.08.21.20179382.short
4100  - http://medrxiv.org/content/early/2020/08/25/2020.08.21.20179382.full
AB  - Background In clinical trials of therapies for uncomplicated Plasmodium falciparum, there are usually some patients who fail treatment even in the absence of drug resistance. Treatment failures are categorised as ‘clinical’ or ‘parasitological’ failures, the latter indicating that recrudescence of the infection has occurred without inducing the return of symptoms. Asymptomatic treatment failure has public health implications for continued malaria transmission and may be important for the spread of drug-resistant malaria. As the number of treatment failures in an individual trial is often low, it is difficult to assess how commonplace asymptomatic treatment failure is, and with what factors it is associated.Methods A systematic literature review was carried out on clinical trials of artemether-lumefantrine (AL) in patients seeking treatment for symptomatic uncomplicated falciparum malaria, and information on symptoms during treatment failure was recorded. Only treatment failures examined by polymerase chain reaction (PCR) were included, so as to exclude reinfections. Using a multivariable Bayesian regression model, we explored factors potentially explaining the proportion of recrudescent infections which are symptomatic across the trials included in our study.Results Across 60 published trials including 9137 malaria patients we found that 40.8% (95% CIs [35.9-45.8%]) of late treatment failures were symptomatic. We found a positive association between transmission intensity and the observed proportion of treatment failures that were asymptomatic. We also found that symptoms were more likely to return in trials that only enrolled children aged < 72 months (odds ratio =1.62, 95% CIs [1.01,2.59]). However, 84 studies had to be excluded from our analysis, as treatment failures were not specified as symptomatic or asymptomatic.Conclusions AL, the most widely used treatment for uncomplicated Plasmodium falciparum in Africa, remains a highly efficacious drug in most endemic countries. However in the small proportion of patients where AL does not clear parasitaemia, the majority of patients do not develop symptoms again and thus would be unlikely to seek another course of treatment. This continued asymptomatic parasite carriage in patients who have been treated may have implications for drug-resistant parasites being introduced into high-transmissions settings.Competing Interest StatementLCO declares prior grant funding from the World Health Organization in addition to the funding already declared in the acknowledgements. The other authors declare that they have no competing interests.Funding StatementLCO acknowledges funding from a UK Royal Society Dorothy Hodgkin fellowship, Medicines for Malaria Venture, the Bill & Melinda Gates Foundation. LCO and JDC acknowledge joint Centre funding from the UK Medical Research Council and DFID under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union (MR/R015600/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code will be available upon reasonable request after publication